Home Press Releases Brachytherapy Seeds Market Poised for Expansion as Hospitals and Cancer Institutes Boost Demand for Targeted Oncology Solutions

Brachytherapy Seeds Market Poised for Expansion as Hospitals and Cancer Institutes Boost Demand for Targeted Oncology Solutions

by Newsroom


(PharmaNewsWire.Com, April 15, 2025 ) InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the ” Brachytherapy Seeds Market – (By Radioactive Seed Type (Iodine-125, Palladium-103, Cesium-131, Others), By Technique (HDR Brachytherapy, LDR Brachytherapy), By Application (Gynecological Cancer, Prostate Cancer, Breast Cancer, Brain Cancer, Others), By End-user (Hospitals, Cancer Institutes, Others)), Trends, Industry Competition Analysis, Revenue and Forecast To 2034.”

According to the latest research by InsightAce Analytic, the Brachytherapy Seeds Imaging Market is valued at USD 137.7 Mn in 2024, and it is expected to reach USD 224.1 Mn by the year 2034, with a CAGR of 5.2% during the forecast period of 2025-2034.

Global Brachytherapy Seeds Market 2025-2034 full Research Repot latest version is now available.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2968

Brachytherapy seeds are tiny radioactive pellets, typically the size of a grain of rice, used in internal radiation therapy to treat cancers—most commonly prostate cancer, but also head and neck, breast, and cervical cancers. The brachytherapy seeds market is experiencing substantial growth due to the introduction of brachytherapy services, which have expanded the treatment options available to cancer patients.

Healthcare facilities attract an increasing number of patients who are seeking effective alternatives to conventional radiation therapy as they broaden their offerings to include this minimally invasive, targeted approach. The capacity of brachytherapy to deliver concentrated doses of radiation directly to tumours while preserving healthy tissue enhances patient satisfaction and outcomes.

Innovations in software, specialized needles, and fiducial markers are also improving the precision, localization, and treatment planning of tumours. The market is being further stimulated by the ongoing research that supports the effectiveness of brachytherapy and the increasing adoption of less invasive treatments.

Furthermore, both patients and healthcare providers are encouraging the adoption of shorter treatment durations and reduced adverse effects. Moreover, the institute is the first government medical college in the state to possess such sophisticated technology, thereby addressing a critical gap in North Karnataka, where comparable services are not accessible in private institutions. In the past, patients who required brachytherapy were referred to institutions in Bengaluru and Hubballi.

List of Prominent Players in the Brachytherapy Seeds Market:

• Argon Medical
• Carl Zeiss AG
• Eckert & Ziegler BEBIG
• Elekta AB
• Icad, Inc.
• Isoaid
• Isoray Medical, Inc.
• Merit Medical Systems, Inc.
• Siemens AG
• Theragenics Corporation

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-04

Market Dynamics:
Drivers-
The market for brachytherapy seed is rapidly expanding as a result of the rising incidence of malignancies, including prostate, breast, and cervical cancers. Healthcare providers are being incentivized to invest in brachytherapy apparatus and services through subsidies, grants, and awareness programs, which subsequently reinforces the expansion of cancer care infrastructure.

The treatment approach is gaining popularity due to its ability to deliver precise and effective cancer therapy, either as a primary treatment or in conjunction with other methods. The demand for sophisticated treatment options, such as brachytherapy, is increasing as the number of cancer cases continues to rise.

Challenges:
However, Brachytherapy necessitates specialized apparatus and infrastructure for patient safety, radiation delivery, and treatment planning, which can be expensive to establish initially. This substantial initial investment can pose a challenge for healthcare facilities, particularly in regions with restricted resources, resulting in a delayed adoption of brachytherapy.

Furthermore, the brachytherapy market may be susceptible to competition from alternative treatments such as chemotherapy, surgery, and external beam radiation therapy.

Regional Trends:
The North America Brachytherapy seeds market is expected to record a largest market revenue share and is projected to grow at a high CAGR in the near future. This was the result of the ongoing development of healthcare technology in the region.

North America’s dedication to innovation, coupled with substantial investments in research and development, has led to the development of innovative brachytherapy solutions that address a wide range of medical requirements.

The demand for targeted treatments, such as brachytherapy, has increased in North America due to the high prevalence of cancer. The increasing awareness of the advantages of this therapy among patients and healthcare professionals additionally bolsters the region’s market dominance.

Regional expansion is additionally encouraged by favourable reimbursement and regulatory environments. Furthermore, the investment environment in the region has undergone a significant transformation, and to preserve their market share and presence, companies are now investing in the development of new products and collaborating with emergent companies.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2968

Recent Developments:
• In March 2024, Eckert & Ziegler BEBIG GmbH, a subsidiary of Eckert & Ziegler SE specializing in brachytherapy solutions for treating prostate, brain, and ocular cancers, achieved a significant milestone by obtaining the Medical Device Regulation (MDR) certificate for its proprietary prostate seeds from DEKRA Certification B.V.. This certification ensures a high level of patient safety and guarantees the long-term availability of these seeds within the European Union.

Segmentation of Brachytherapy Seeds Market-
By Radioactive Seed Type-
• lodine-125
• Palladium-103
• Cesium-131
• Others
By Technique-
• HRD Brachytherapy
• LDR Brachytherapy
By Application-
• Gynecological Cancer
• Prostate Cancer
• Breast Cancer
• Brain Cancer
• Others
By End-user-
• Hospitals
• Cancer Institutes
• Others
By Region-
North America-
• The US
• Canada
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Mexico
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com

Insight Ace Analytics
Diana D’souza
+1 551 226 6109
diana.dsouza@insightaceanalytics.com

Source: EmailWire.Com



Source link

You may also like

About Us

Pharma Newswire™ aggregates, publishes and distributes news in the Pharmaceutical Industry. In association with EmailWire, Pharma Newswire™ provides press release distribution services in the pharmaceutical sector. Press releases are disseminated to journalists, experts, investors, trade publications and other related media outlets. To send a press release, contact us through the following messaging apps:

Pharma Newswire™ is part of GroupWeb Media Network. © 2025 GroupWeb Media LLC